Bruker (Bruker) Total Current Assets

: $2,164 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Bruker's total current assets for the quarter that ended in Dec. 2023 was $2,164 Mil.

Bruker Total Current Assets Historical Data

The historical data trend for Bruker's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bruker Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

1,796.30

1,925.00

2,471.80

2,113.20

2,164.20

Bruker Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															2,113.20	2,133.00	2,183.30	2,029.40	2,164.20

Bruker Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Bruker's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	488.3	+	621.8	+	968.3	+	85.8
	=	2,164

Bruker's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	488.3	+	621.8	+	968.3	+	85.8
	=	2,164

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Bruker (NAS:BRKR) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Bruker's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	488.3	-	2836.6	+	0.75 * 492	+	0.5 * 968.3
=	-1,495

Bruker Total Current Assets Related Terms

Thank you for viewing the detailed overview of Bruker's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Bruker (Bruker) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bruker Corp (NAS:BRKR) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

BKD:Germany

Address

40 Manning Road, Billerica, MA, USA, 01821

Website

https://www.bruker.com

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives a majority of its revenue from Europe.

Executives

Frank H Laukien	director, 10 percent owner, officer: CEO, President	C/O BRUKER DALTONICS, 40 MANNING ROAD, BILLERICA MA 01821
Marc A Kastner	director	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Cynthia M Friend	director	C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Richard A Packer	director	9 KENDALL DRIVE, WESTBOROUGH MA 01581
Philip Ma	director	C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Mark Munch	officer: Pres. Bruker Nano Inc.	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Juergen Srega	officer: Group President Bruker CALID	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Burkhard Prause	officer: Pres. & CEO, Bruker EST	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Bonnie H Anderson	director	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Martin Gilles Gerard Jean	director	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Falko Busse	officer: President, BioSpin Group	40 MANNING ROAD, BILLERICA MA 01821
Gerald N Herman	officer: Vice President, Corp Contr.	55 EXECUTIVE DRIVE, HUDSON NH 03051
Ingen Chris Van	director	395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Richard Kniss	director	395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Adelene Q Perkins	director	C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139